DE69534741D1 - In hefe exprimierte heteologe g-protein-gekoppelte rezeptoren, fusionen desselben mit g-proteinen und deren verwendung im biotest - Google Patents

In hefe exprimierte heteologe g-protein-gekoppelte rezeptoren, fusionen desselben mit g-proteinen und deren verwendung im biotest

Info

Publication number
DE69534741D1
DE69534741D1 DE69534741T DE69534741T DE69534741D1 DE 69534741 D1 DE69534741 D1 DE 69534741D1 DE 69534741 T DE69534741 T DE 69534741T DE 69534741 T DE69534741 T DE 69534741T DE 69534741 D1 DE69534741 D1 DE 69534741D1
Authority
DE
Germany
Prior art keywords
protein
heterologous
expressed
yeast
hepeologist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534741T
Other languages
English (en)
Other versions
DE69534741T2 (de
Inventor
Henry Pausch
Alton Ozenberger
Richard Hadcock
Alicia Price
Marie Kajkowski
Richard Kirsch
Tardy Chaleff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22722547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69534741(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Publication of DE69534741D1 publication Critical patent/DE69534741D1/de
Application granted granted Critical
Publication of DE69534741T2 publication Critical patent/DE69534741T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69534741T 1994-02-14 1995-02-14 In hefe exprimierte heteologe g-protein-gekoppelte rezeptoren, fusionen desselben mit g-proteinen und deren verwendung im biotest Expired - Lifetime DE69534741T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US195729 1980-10-10
US08/195,729 US5691188A (en) 1994-02-14 1994-02-14 Transformed yeast cells expressing heterologous G-protein coupled receptor
PCT/US1995/002075 WO1995021925A1 (en) 1994-02-14 1995-02-14 Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay

Publications (2)

Publication Number Publication Date
DE69534741D1 true DE69534741D1 (de) 2006-04-06
DE69534741T2 DE69534741T2 (de) 2006-11-02

Family

ID=22722547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534741T Expired - Lifetime DE69534741T2 (de) 1994-02-14 1995-02-14 In hefe exprimierte heteologe g-protein-gekoppelte rezeptoren, fusionen desselben mit g-proteinen und deren verwendung im biotest

Country Status (9)

Country Link
US (6) US5691188A (de)
EP (1) EP0745130B1 (de)
JP (1) JPH09510087A (de)
AT (1) ATE315657T1 (de)
AU (1) AU1846995A (de)
CA (1) CA2183166A1 (de)
DE (1) DE69534741T2 (de)
SG (1) SG49061A1 (de)
WO (1) WO1995021925A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235648B1 (en) 1993-03-31 2007-06-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7416881B1 (en) * 1993-03-31 2008-08-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6864060B1 (en) 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
US6255059B1 (en) 1993-03-31 2001-07-03 Cadus Pharmaceutical Corporation Methods for identifying G protein coupled receptor effectors
US20030054402A1 (en) * 1993-03-31 2003-03-20 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
AU6110896A (en) * 1995-06-07 1996-12-30 Cadus Pharmaceutical Corporation Expression of functional vertebrate phospholipases in yeast
EP0862614A1 (de) * 1995-09-20 1998-09-09 Molecular Geriatrics Corporation Hefe rezeptor und g-protein fusionsprotein
WO1997024457A1 (en) 1995-12-29 1997-07-10 Guilford Pharmaceuticals Inc. Method and kit for detection of multiple protein interactions
GB9606126D0 (en) * 1996-03-22 1996-05-22 British Biotech Pharm Biosensors
AU3055697A (en) * 1996-04-23 1997-11-12 Cadus Pharmaceutical Corporation Functional expression of heterologous adenylyl cyclase
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
US6485922B1 (en) 1997-10-10 2002-11-26 Atairgin Technologies, Inc. Methods for detecting compounds which modulate the activity of an LPA receptor
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
US6355473B1 (en) 1998-05-06 2002-03-12 Cadus Pharmaceutical Corp. Yeast cells having mutations in stp22 and uses therefor
US6733991B1 (en) * 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
US6280934B1 (en) 1998-05-13 2001-08-28 Millennium Pharmaceuticals, Inc. Assay for agents which alter G-protein coupled receptor activity
AU4820399A (en) * 1998-06-29 2000-01-17 Hyseq, Inc. A chemokine receptor obtained from a cdna library of fetal liver-spleen
US7081360B2 (en) * 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7273747B2 (en) * 1998-08-27 2007-09-25 Cadus Technologies, Inc. Cell having amplified signal transduction pathway responses and uses therefor
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
EP1123391A2 (de) * 1998-09-01 2001-08-16 BASF Aktiengesellschaft Verfahren zur verbesserung der funktion von heterologen g-protein-gekoppelten rezeptoren
US6251605B1 (en) 1998-10-27 2001-06-26 Cadus Pharmaceutical Corporation Yeast cells having mutations in Cav1 and uses therefor
US6902886B1 (en) * 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
US6420137B1 (en) 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor
US6504008B1 (en) 1999-02-01 2003-01-07 Cadus Technologies, Inc. Cell based signal generation
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US6555325B1 (en) 1999-06-14 2003-04-29 Cadus Technologies, Inc. System for detection of a functional interaction between a compound and a cellular signal transduction component
US7223533B2 (en) 1999-09-10 2007-05-29 Cadus Technologies, Inc. Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
US6818739B2 (en) 1999-12-03 2004-11-16 Ndsu Research Foundation Somatostatins
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
AU2001259512B2 (en) 2000-05-04 2007-03-01 Yale University High density protein arrays for screening of protein activity
DE60143959D1 (de) 2000-08-25 2011-03-10 Basf Plant Science Gmbh En kodieren
WO2002035231A1 (en) * 2000-10-26 2002-05-02 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7176187B2 (en) * 2001-02-15 2007-02-13 Board Of Regents, The University Of Texas System Fusion proteins based upon somatostatin receptors
US20040245317A1 (en) * 2001-04-06 2004-12-09 Vladimir Larionov Artificial chromosomes that can shuttle between bacteria yeast and mammalian cells
WO2002083934A1 (en) * 2001-04-17 2002-10-24 Wyeth P2yac receptor involved in platelet aggregation
CN1527720A (zh) * 2001-05-11 2004-09-08 Ү³��ѧ 利用蛋白组芯片全面分析蛋白活性
US20030166540A1 (en) * 2001-05-30 2003-09-04 Feder John N. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY30
BR0210283A (pt) * 2001-06-07 2004-09-14 Wyeth Corp Receptor acoplado à proteìna-g e usos para o mesmo
EP2293067B1 (de) 2001-06-26 2016-04-20 Senomyx, Inc. Hetero-oligomere T1R-Geschmacksrezeptoren und diese Rezeptoren exprimierende Zelllinien und deren Verwendung zur Identifizierung von Geschmacksverbindungen
EP1414443B1 (de) * 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOCHINOLINON-DERIVATE
JP4319908B2 (ja) 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
AU2002332027A1 (en) * 2001-10-04 2003-04-14 The Government Of The United States Of America, As Tandem repeat markers
US7445925B2 (en) * 2001-10-27 2008-11-04 Sanofi-Aventis Deutschland Gmbh Aequorin as a reporter gene in yeast
US20030232359A1 (en) * 2002-03-18 2003-12-18 Ramanathan Chandra S. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY40_2
PL208481B1 (pl) 2002-04-23 2011-05-31 Cargill Sposób wytwarzania monatyny
DE10233516A1 (de) * 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
US20040248323A1 (en) 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
MX2007001195A (es) 2004-07-30 2007-10-03 Cargill Inc Alanina 2,3-aminomutasas.
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
EP1889846A1 (de) * 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US7674891B2 (en) 2008-08-01 2010-03-09 International Flavors & Fragrances Inc. Nucleic acid molecules encoding GPR84
US20100209931A1 (en) * 2009-02-13 2010-08-19 Yolanda Sanchez Compositions for Identifying Novel Compositions for the Treatment of Disease and Methods of Using Same
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US9937115B2 (en) 2010-10-01 2018-04-10 The Procter & Gamble Company Oral care compositions with improved flavor
MX2013004364A (es) 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
EP2661266B1 (de) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Auf chemosensorischen rezeptorliganden basierende therapien
WO2013113370A1 (en) * 2012-01-31 2013-08-08 Canvax Biotech S.L Gpcr with improved cell surface expression
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9809862B2 (en) * 2014-08-11 2017-11-07 Georgia Tech Research Corporation G-protein coupled receptor (GPCR)-based biosensors and uses thereof
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EP3649236A4 (de) * 2017-07-05 2021-04-07 The Regents of The University of California Multiplex-rezeptor-ligand-interaktionsschirme
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
IL281423B2 (en) 2018-09-20 2024-08-01 Iovance Biotherapeutics Inc Expansion of TILS from cryopreserved tumor samples
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (de) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
EP4512828A3 (de) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Verfahren zur ex-vivo-anreicherung und vermehrung von tumorreaktiven t-zellen und verwandten zusammensetzungen davon
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4259164A1 (de) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit braf-hemmern und/oder mek-hemmern
EP4262827A1 (de) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Behandlung von krebs mit tumorinfiltrierenden lymphozyten
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022246003A2 (en) * 2021-05-18 2022-11-24 The Trustees Of Columbia University In The City Of New York Live yeast biosensors and methods of use thereof
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925791A (en) * 1984-07-20 1990-05-15 Celltech Limited Eucaryotic expression vectors
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
DK0548165T3 (da) 1990-09-13 2001-07-16 Univ Duke Ekspression af G-proteinkoblede receptorer i gær
DK0692025T3 (da) * 1993-03-31 2002-02-11 Cadus Pharmaceutical Corp Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5789184A (en) * 1993-03-31 1998-08-04 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor

Also Published As

Publication number Publication date
US6406871B1 (en) 2002-06-18
US20090081764A1 (en) 2009-03-26
CA2183166A1 (en) 1995-08-17
US5691188A (en) 1997-11-25
US20040023315A1 (en) 2004-02-05
WO1995021925A1 (en) 1995-08-17
EP0745130A1 (de) 1996-12-04
SG49061A1 (en) 1998-05-18
US6607906B1 (en) 2003-08-19
DE69534741T2 (de) 2006-11-02
JPH09510087A (ja) 1997-10-14
ATE315657T1 (de) 2006-02-15
EP0745130B1 (de) 2006-01-11
US5846819A (en) 1998-12-08
US7148053B2 (en) 2006-12-12
AU1846995A (en) 1995-08-29

Similar Documents

Publication Publication Date Title
DE69534741D1 (de) In hefe exprimierte heteologe g-protein-gekoppelte rezeptoren, fusionen desselben mit g-proteinen und deren verwendung im biotest
NZ515913A (en) Modified chimeric polypeptides with improved pharmacokinetic properties
CA2299624A1 (en) Mammalian cytokine receptor - 11
Buggy et al. Glucagon· Glucagon-like Peptide I Receptor Chimeras Reveal Domains That Determine Specificity of Glucagon Binding (∗)
EP1369430A3 (de) Zwei menschliche G-Protein-gekoppelte Rezeptorproteine: EBV-induzierter GPCR (EBI-2) und EGD-1-ählicher GPCR
PT96714A (pt) Processo para a preparacao de receptores acoplados a proteina g hibrida
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
NZ336929A (en) Purified receptor that binds TRAIL and antibodies thereof
CA2335318A1 (en) Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
EP1029915A3 (de) Expression von an G-Protein gekoppelten Rezeptoren in Hefe
ATE191503T1 (de) Somatostatinrezeptoren
CA2378519A1 (en) Human cytokine receptor
Svoboda et al. A cDNA construct allowing the expression of rat hepatic glucagon receptors
IL138593A (en) Glial factor receptor ??3 (gfr??3) polypeptide, nucleic acid encoding the same, process for preparation thereof, vectors, host cells, antibodies, chimeric molecules and use of such gfr??3
Long In search of a function for the invariant chain associated with la antigens
ATE291627T1 (de) Chimäre des g-proteins
TW200510456A (en) Materials and methods relating to g-protein coupled receptor oligomers
KR950703057A (ko) 글루카곤 수용체(glucagon receptors)
AU2003293959A1 (en) Millisecond activation switch for seven-transmembrane proteins
Gourlet et al. Analogues of VIP, Helodermin, and PACAP Discriminate between Rat and Human VIP1 and VIP2 Receptors a
Hasegawa et al. Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin
WO1999023116B1 (en) ASSAY EMPLOYING CadC FUSION PROTEINS
Molina et al. Structural domains of the insulin receptor and IGF receptor required for dimerisation and ligand binding
Wittenbrink et al. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain
IL138585A (en) Vertebrate patched -2 protein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH, MADISON, N.J., US